-
Autor
Brönimann, Stephan 1 Carrion, Diego M 1 D'Andrea, David 1 De Berardinis, Ettore 1 Del Giudice, Francesco 1 Di Maida, Fabrizio 1 Di Trapani, Ettore 1 Filippot, Ronan 1 Grisay, Guillaume 1 Hendricksen, Kees 1 Krajewski, Wojciech 1 Laukhtina, Ekaterina 1 Maggi, Martina 1 Mari, Andrea 1 Mertens, Laura S 1 Moschini, Marco 1 Paulnsteiner, David 1 Pichler, Renate 1 Pradere, Benjamin 1 Shariat, Shahrokh F 1
- Organizace
-
Pracoviště
Department of Cancer Medicine Institu... 1 Department of Experimental and Clinic... 1 Department of Internal Medicine 2 Uni... 1 Department of Maternal Infant and Uro... 1 Department of Minimally Invasive and ... 1 Department of Urology 2nd Faculty of ... 1 Department of Urology AOU Città della... 1 Department of Urology European Instit... 1 Department of Urology Hospital Univer... 1 Department of Urology IRCCS Ospedale ... 1 Department of Urology Medical Univers... 1 Department of Urology Medical Univers... 1 Department of Urology The Netherlands... 1 Department of Urology Torrejon Univer... 1 Department of Urology University of T... 1 Department of Urology Weill Cornell M... 1 Francisco de Vitoria University Madri... 1 Hourani Center for Applied Scientific... 1 Institute for Urology and Reproductiv... 1
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Nejvíce citované
-
Autor
Brönimann, Stephan 1 Carrion, Diego M 1 D'Andrea, David 1 De Berardinis, Ettore 1 Del Giudice, Francesco 1 Di Maida, Fabrizio 1 Di Trapani, Ettore 1 Filippot, Ronan 1 Grisay, Guillaume 1 Hendricksen, Kees 1 Krajewski, Wojciech 1 Laukhtina, Ekaterina 1 Maggi, Martina 1 Mari, Andrea 1 Mertens, Laura S 1 Moschini, Marco 1 Paulnsteiner, David 1 Pichler, Renate 1 Pradere, Benjamin 1 Shariat, Shahrokh F 1
- Organizace
-
Pracoviště
Department of Cancer Medicine Institu... 1 Department of Experimental and Clinic... 1 Department of Internal Medicine 2 Uni... 1 Department of Maternal Infant and Uro... 1 Department of Minimally Invasive and ... 1 Department of Urology 2nd Faculty of ... 1 Department of Urology AOU Città della... 1 Department of Urology European Instit... 1 Department of Urology Hospital Univer... 1 Department of Urology IRCCS Ospedale ... 1 Department of Urology Medical Univers... 1 Department of Urology Medical Univers... 1 Department of Urology The Netherlands... 1 Department of Urology Torrejon Univer... 1 Department of Urology University of T... 1 Department of Urology Weill Cornell M... 1 Francisco de Vitoria University Madri... 1 Hourani Center for Applied Scientific... 1 Institute for Urology and Reproductiv... 1
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Nejvíce citované
- D'Andrea, David
-
Shariat, Shahrokh F
Autor Shariat, Shahrokh F Department of Urology, Medical University of Vienna, Vienna, Austria Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA Department of Urology, Weill Cornell Medical College, New York, NY, USA Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
- Soria, Francesco
- Mari, Andrea
- Mertens, Laura S
- Di Trapani, Ettore
- Carrion, Diego M
- Pradere, Benjamin
- Pichler, Renate
- Filippot, Ronan
PubMed
35813257
PubMed Central
PMC9257642
DOI
10.1016/j.euros.2022.05.001
PII: S2666-1683(22)00607-3
Knihovny.cz E-zdroje
BACKGROUND: There might be differential sensitivity to neoadjuvant chemotherapy (NAC) in patients with primary muscle-invasive bladder cancer (MIBC) in comparison to patients with secondary MIBC after a history of non-muscle-invasive disease. OBJECTIVE: To investigate pathologic response rates and survival associated with primary versus secondary MIBC among patients treated with cisplatin-based NAC for cT2-4N0M0 MIBC. DESIGN SETTING AND PARTICIPANTS: Oncologic outcomes were compared for 350 patients with primary MIBC and 64 with secondary MIBC treated with NAC and radical cystectomy between 1992 and 2021 at 11 academic centers. Genomic analyses were performed for 476 patients from the Memorial Sloan Kettering/The Cancer Genome Atlas cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome measures were pathologic objective response (pOR; ≤ypT1 N0), pathologic complete response (pCR; ypT0 N0), overall mortality, and cancer-specific mortality. RESULTS AND LIMITATIONS: The primary MIBC group had higher pOR (51% vs 34%; p = 0.02) and pCR (33% vs 17%; p = 0.01) rates in comparison to the secondary MIBC group. On multivariable logistic regression analysis, primary MIBC was independently associated with both pOR (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.26-0.87; p = 0.02) and pCR (OR 0.41, 95% CI 0.19-0.82; p = 0.02). However, on multivariable Cox regression analysis, primary MIBC was not associated with overall mortality (hazard ratio 1.70, 95% CI 0.84-3.44; p = 0.14) or cancer-specific mortality (hazard ratio 1.50, 95% CI 0.66-3.40; p = 0.3). Genomic analyses revealed a significantly higher ERCC2 mutation rate in primary MIBC than in secondary MIBC (12.4% vs 1.3%; p < 0.001). CONCLUSIONS: Patients with primary MIBC have better pathologic response rates to NAC in comparison to patients with secondary MIBC. Chemoresistance might be related to the different genomic profile of primary versus secondary MIBC. PATIENT SUMMARY: We investigated the treatment response to neoadjuvant chemotherapy (NAC; chemotherapy received before the primary course of treatment) and survival for patients with a primary diagnosis of muscle-invasive bladder cancer (MIBC) in comparison to patients with a history of non-muscle-invasive bladder cancer that progressed to MIBC. Patients with primary MIBC had a better response to NAC but this did not translate to better survival after accounting for other tumor characteristics.
- Klíčová slova
- Bladder cancer, Neoadjuvant chemotherapy, Primary, Response, Secondary, Survival,
- Publikační typ
- časopisecké články MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.